{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:16:42Z","timestamp":1791227802517,"version":"4.1.0"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40263-025-01226-z","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T14:43:09Z","timestamp":1757688189000},"page":"1201-1220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer\u2019s Disease and Parkinson\u2019s Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1\/GIP Receptor Agonists as Potential Disease-Modifying Therapies"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-3260","authenticated-orcid":false,"given":"Christian","family":"H\u00f6lscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"9","key":"1226_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.17219\/acem\/171379","volume":"32","author":"M Kurkinen","year":"2023","unstructured":"Kurkinen M. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer\u2019s disease. Adv Clin Exp Med. 2023;32(9):943\u20137.","journal-title":"Adv Clin Exp Med."},{"issue":"2","key":"1226_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15(2):73\u201388.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1226_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3233\/JAD-230099","volume":"94","author":"KP Kepp","year":"2023","unstructured":"Kepp KP, Sensi SL, Johnsen KB, Barrio JR, Hoilund-Carlsen PF, Neve RL, et al. The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes. J Alzheimers Dis. 2023;94(2):497\u2013507.","journal-title":"J Alzheimers Dis"},{"key":"1226_CR4","doi-asserted-by":"crossref","unstructured":"Espay AJ, Kepp KP, Herrup K. Lecanemab and donanemab as therapies for Alzheimer\u2019s disease: an illustrated perspective on the data. eNeuro. 2024;11(7).","DOI":"10.1523\/ENEURO.0319-23.2024"},{"issue":"3","key":"1226_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3233\/JAD-2010-091504","volume":"20","author":"L Mosconi","year":"2010","unstructured":"Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer\u2019s disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis. 2010;20(3):843\u201354.","journal-title":"J Alzheimers Dis"},{"issue":"1 Suppl","key":"1226_CR6","first-page":"S55","volume":"10","author":"GD Femminella","year":"2014","unstructured":"Femminella GD, Edison P. Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2014;10(1 Suppl):S55-61.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc."},{"key":"1226_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/583931","volume":"2015","author":"M Bailly","year":"2015","unstructured":"Bailly M, Destrieux C, Hommet C, Mondon K, Cottier JP, Beaufils E, et al. Precuneus and cingulate cortex atrophy and hypometabolism in patients with Alzheimer\u2019s disease and mild cognitive impairment: MRI and (18)F-FDG PET quantitative analysis using FreeSurfer. Biomed Res Int. 2015;2015:583931.","journal-title":"Biomed Res Int"},{"issue":"3","key":"1226_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.nbd.2008.08.001","volume":"32","author":"P Edison","year":"2008","unstructured":"Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer\u2019s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32(3):412\u20139.","journal-title":"Neurobiol Dis"},{"key":"1226_CR9","doi-asserted-by":"crossref","unstructured":"Yonamine CY, Michalani MLE, Moreira RJ, Machado UF. Glucose transport and utilization in the hippocampus: from neurophysiology to diabetes-related development of dementia. Int J Mol Sci. 2023;24(22).","DOI":"10.3390\/ijms242216480"},{"issue":"s1","key":"1226_CR10","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.3233\/JAD-240069","volume":"101","author":"SM de la Monte","year":"2024","unstructured":"de la Monte SM. Conquering insulin network dysfunctions in Alzheimer\u2019s disease: where are we today? J Alzheimers Dis. 2024;101(s1):S317\u201343.","journal-title":"J Alzheimers Dis"},{"key":"1226_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cells12162019","author":"S Raut","year":"2023","unstructured":"Raut S, Bhalerao A, Powers M, Gonzalez M, Mancuso S, Cucullo L. Hypometabolism, Alzheimer\u2019s disease, and possible therapeutic targets: an overview. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12162019.","journal-title":"Cells"},{"issue":"3","key":"1226_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0167-4943(82)90021-8","volume":"1","author":"S Hoyer","year":"1982","unstructured":"Hoyer S. The abnormally aged brain. Its blood flow and oxidative metabolism. A review\u2014Part II. Arch Gerontol Geriatr. 1982;1(3):195\u2013207.","journal-title":"Arch Gerontol Geriatr"},{"issue":"3","key":"1226_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF00314304","volume":"235","author":"S Hoyer","year":"1988","unstructured":"Hoyer S, Oesterreich K, Wagner O. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol. 1988;235(3):143\u20138.","journal-title":"J Neurol"},{"issue":"3\u20135","key":"1226_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/0278-5846(86)90018-7","volume":"10","author":"S Hoyer","year":"1986","unstructured":"Hoyer S. Senile dementia and Alzheimer\u2019s disease. Brain blood flow and metabolism. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3\u20135):447\u201378.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1226_CR15","first-page":"146","volume":"64","author":"A Alzheimer","year":"1907","unstructured":"Alzheimer A. Ueber eine eigenartige Erkrankung der Hirnrinde. Zeitschrift fuer Psychiatrie. 1907;64:146\u20139.","journal-title":"Zeitschrift fuer Psychiatrie."},{"issue":"6","key":"1226_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"A Alzheimer","year":"1995","unstructured":"Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer\u2019s 1907 paper, \u201c\u00dcber eine eigenartige Erkankung der Hirnrinde.\u201d Clin Anat. 1995;8(6):429\u201331.","journal-title":"Clin Anat"},{"issue":"8","key":"1226_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.bbalip.2010.05.004","volume":"1801","author":"P Foley","year":"2010","unstructured":"Foley P. Lipids in Alzheimer\u2019s disease: a century-old story. Biochim Biophys Acta. 2010;1801(8):750\u20133.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1226_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12800-8","volume":"272","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Zhao G, Zhao Y. Dysregulation of energy metabolism in Alzheimer\u2019s disease. J Neurol. 2024;272(1):2.","journal-title":"J Neurol"},{"issue":"4","key":"1226_CR19","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Investig. 2012;122(4):1316\u201338.","journal-title":"J Clin Investig"},{"issue":"145","key":"1226_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","volume":"3","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T. Insulin resistance and Parkinson\u2019s disease: a new target for disease modification? Prog Neurobiol. 2016;3(145):98\u2013120.","journal-title":"Prog Neurobiol"},{"issue":"2","key":"1226_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/156720507780362137","volume":"4","author":"S Craft","year":"2007","unstructured":"Craft S. Insulin resistance and Alzheimer\u2019s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4(2):147\u201352.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"1226_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JAD-2005-7106","volume":"7","author":"SM de la Monte","year":"2005","unstructured":"de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer\u2019s disease. J Alzheimers Dis. 2005;7(1):45\u201361.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1226_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.neurobiolaging.2008.04.002","volume":"31","author":"AM Moloney","year":"2010","unstructured":"Moloney AM, Griffin RJ, Timmons S, O\u2019Connor R, Ravid R, O\u2019Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1\/2 in Alzheimer\u2019s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31(2):224\u201343.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"1226_CR24","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","volume":"53","author":"A Ott","year":"1999","unstructured":"Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam study. Neurology. 1999;53(9):1937\u201342.","journal-title":"Neurology"},{"issue":"9","key":"1226_CR25","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1212\/WNL.53.9.1959","volume":"53","author":"KM Mehta","year":"1999","unstructured":"Mehta KM, Ott A, Kalmijn S, Slooter AJ, van Duijn CM, Hofman A, et al. Head trauma and risk of dementia and Alzheimer\u2019s disease: The Rotterdam study. Neurology. 1999;53(9):1959\u201362.","journal-title":"Neurology"},{"issue":"12","key":"1226_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1212\/WNL.0b013e31822f0435","volume":"77","author":"T Ohara","year":"2011","unstructured":"Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, et al. Glucose tolerance status and risk of dementia in the community: The Hisayama study. Neurology. 2011;77(12):1126\u201334.","journal-title":"Neurology"},{"key":"1226_CR27","doi-asserted-by":"publisher","first-page":"1548020","DOI":"10.3389\/fnagi.2025.1548020","volume":"17","author":"X Li","year":"2025","unstructured":"Li X, Zeng Z. Exploring the link between estimated glucose disposal rate and Parkinson\u2019s disease: cross-sectional and mortality analysis of NHANES 2003\u20132016. Front Aging Neurosci. 2025;17:1548020.","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"1226_CR28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/mds.29122","volume":"37","author":"D Athauda","year":"2022","unstructured":"Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M, et al. The impact of type 2 diabetes in Parkinson\u2019s disease. Mov Disord. 2022;37(8):1612\u201323.","journal-title":"Mov Disord"},{"issue":"10","key":"1226_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JPD-191900","volume":"24","author":"JLY Cheong","year":"2020","unstructured":"Cheong JLY, de Pablo-Fernandez E, Foltynie T, Noyce AJ. The association between type 2 diabetes mellitus and Parkinson\u2019s disease. J Parkinson\u2019s Dis. 2020;24(10):775\u201389.","journal-title":"J Parkinson\u2019s Dis"},{"issue":"4","key":"1226_CR30","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2337\/dc06-2011","volume":"30","author":"G Hu","year":"2007","unstructured":"Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson\u2019s disease. Diabetes Care. 2007;30(4):842\u20137.","journal-title":"Diabetes Care"},{"key":"1226_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.626636","volume":"15","author":"N Kyrtata","year":"2021","unstructured":"Kyrtata N, Emsley HCA, Sparasci O, Parkes LM, Dickie BR. A systematic review of glucose transport alterations in Alzheimer\u2019s disease. Front Neurosci. 2021;15:626636.","journal-title":"Front Neurosci"},{"key":"1226_CR32","doi-asserted-by":"crossref","unstructured":"Yanai H, Adachi H, Hakoshima M, Katsuyama H. Pathology and treatments of Alzheimer\u2019s disease based on considering changes in brain energy metabolism due to type 2 diabetes. Molecules. 2024;29(24).","DOI":"10.3390\/molecules29245936"},{"key":"1226_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1210\/rp.56.1.175","volume":"56","author":"RT Watson","year":"2001","unstructured":"Watson RT, Pessin JE. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res. 2001;56:175\u201393.","journal-title":"Recent Prog Horm Res"},{"issue":"3","key":"1226_CR34","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.neuron.2016.12.020","volume":"93","author":"G Ashrafi","year":"2017","unstructured":"Ashrafi G, Wu Z, Farrell RJ, Ryan TA. GLUT4 mobilization supports energetic demands of active synapses. Neuron. 2017;93(3):606-15 e3.","journal-title":"Neuron"},{"issue":"1","key":"1226_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s10571-025-01555-z","volume":"45","author":"D Na","year":"2025","unstructured":"Na D, Zhang Z, Meng M, Li M, Gao J, Kong J, et al. Energy metabolism and brain aging: strategies to delay neuronal degeneration. Cell Mol Neurobiol. 2025;45(1):38.","journal-title":"Cell Mol Neurobiol"},{"key":"1226_CR36","doi-asserted-by":"crossref","unstructured":"Maszka P, Kwasniak-Butowska M, Cysewski D, Slawek J, Smolenski RT, Tomczyk M. Metabolomic footprint of disrupted energetics and amino acid metabolism in neurodegenerative diseases: perspectives for early diagnosis and monitoring of therapy. Metabolites. 2023;13(3).","DOI":"10.3390\/metabo13030369"},{"issue":"3","key":"1226_CR37","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/alz.12474","volume":"18","author":"HN Yassine","year":"2022","unstructured":"Yassine HN, Solomon V, Thakral A, Sheikh-Bahaei N, Chui HC, Braskie MN, et al. Brain energy failure in dementia syndromes: opportunities and challenges for glucagon-like peptide-1 receptor agonists. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2022;18(3):478\u201397.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc."},{"issue":"4","key":"1226_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/ggi.12176","volume":"14","author":"T Makino","year":"2014","unstructured":"Makino T, Umegaki H, Suzuki Y, Yanagawa M, Nonogaki Z, Nakashima H, et al. Relationship between small cerebral white matter lesions and cognitive function in patients with Alzheimer\u2019s disease and amnestic mild cognitive impairment. Geriatr Gerontol Int. 2014;14(4):819\u201326.","journal-title":"Geriatr Gerontol Int"},{"key":"1226_CR39","doi-asserted-by":"crossref","unstructured":"Yoon JH, Hwang J, Son SU, Choi J, You SW, Park H, et al. How can insulin resistance cause Alzheimer\u2019s disease? Int J Mol Sci. 2023;24(4).","DOI":"10.3390\/ijms24043506"},{"issue":"1","key":"1226_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3233\/JAD-171153","volume":"63","author":"LC Silbert","year":"2018","unstructured":"Silbert LC, Lahna D, Promjunyakul NO, Boespflug E, Ohya Y, Higashiuesato Y, et al. Risk factors associated with cortical thickness and white matter hyperintensities in dementia free Okinawan elderly. J Alzheimers Dis. 2018;63(1):365\u201372.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1226_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/jnnp.2005.069583","volume":"77","author":"GJ Biessels","year":"2006","unstructured":"Biessels GJ, De Leeuw FE, Lindeboom J, Barkhof F, Scheltens P. Increased cortical atrophy in patients with Alzheimer\u2019s disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry. 2006;77(3):304\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1226_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14497","volume":"17","author":"JA Cleary","year":"2025","unstructured":"Cleary JA, Kumar A, Craft S, Deep G. Neuron-derived extracellular vesicles as a liquid biopsy for brain insulin dysregulation in Alzheimer\u2019s disease and related disorders. Alzheimer\u2019s Dement. 2025;17:e14497.","journal-title":"Alzheimer\u2019s Dement."},{"issue":"3","key":"1226_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119452","volume":"10","author":"SF Graham","year":"2015","unstructured":"Graham SF, Chevallier OP, Elliott CT, Holscher C, Johnston J, McGuinness B, et al. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer\u2019s disease. PLoS ONE. 2015;10(3):e0119452.","journal-title":"PLoS ONE"},{"key":"1226_CR44","doi-asserted-by":"crossref","unstructured":"Polis B, Samson AO. A new perspective on Alzheimer\u2019s disease as a brain expression of a complex metabolic disorder. In: Wisniewski T, editor. Alzheimer\u2019s disease, Chapter 1. Brisbane (AU); 2019.","DOI":"10.15586\/alzheimersdisease.2019.ch1"},{"issue":"4","key":"1226_CR45","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1172\/JCI57256","volume":"122","author":"TR Bomfim","year":"2012","unstructured":"Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease-associated Abeta oligomers. J Clin Investig. 2012;122(4):1339\u201353.","journal-title":"J Clin Investig"},{"issue":"3","key":"1226_CR46","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","volume":"37","author":"MG Tansey","year":"2010","unstructured":"Tansey MG, Goldberg MS. Neuroinflammation in Parkinson\u2019s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37(3):510\u20138.","journal-title":"Neurobiol Dis"},{"key":"1226_CR47","volume":"2011","author":"CC Ferrari","year":"2011","unstructured":"Ferrari CC, Tarelli R. Parkinson\u2019s disease and systemic inflammation. Parkinson\u2019s Dis. 2011;2011:436813.","journal-title":"Parkinson\u2019s Dis."},{"issue":"3","key":"1226_CR48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"H Akiyama","year":"2000","unstructured":"Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer\u2019s disease. Neurobiol Aging. 2000;21(3):383\u2013421.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"1226_CR49","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1124\/pr.112.005850","volume":"64","author":"I Clark","year":"2012","unstructured":"Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B. Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer\u2019s disease links numerous treatment rationales. Pharmacol Rev. 2012;64(4):1004\u201326.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1226_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1750-3639.1998.tb00136.x","volume":"8","author":"WS Griffin","year":"1998","unstructured":"Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, et al. Glial-neuronal interactions in Alzheimer\u2019s disease: the potential role of a \u2018cytokine cycle\u2019 in disease progression. Brain Pathol. 1998;8(1):65\u201372.","journal-title":"Brain Pathol"},{"issue":"2","key":"1226_CR51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nri2015","volume":"7","author":"VH Perry","year":"2007","unstructured":"Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007;7(2):161\u20137.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1226_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-023-00336-2","volume":"12","author":"B Yulug","year":"2023","unstructured":"Yulug B, Altay O, Li X, Hanoglu L, Cankaya S, Lam S, et al. Combined metabolic activators improve cognitive functions in Alzheimer\u2019s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Transl Neurodegener. 2023;12(1):4.","journal-title":"Transl Neurodegener."},{"key":"1226_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.807970","volume":"8","author":"M Lilamand","year":"2022","unstructured":"Lilamand M, Mouton-Liger F, Di Valentin E, Sanchez Ortiz M, Paquet C. Efficacy and safety of ketone supplementation or ketogenic diets for Alzheimer\u2019s disease: a mini review. Front Nutr. 2022;8:807970.","journal-title":"Front Nutr"},{"issue":"1","key":"1226_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"CM Karch","year":"2015","unstructured":"Karch CM, Goate AM. Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77(1):43\u201351.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1226_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5114\/fn.2019.85929","volume":"57","author":"RA Armstrong","year":"2019","unstructured":"Armstrong RA. Risk factors for Alzheimer\u2019s disease. Folia Neuropathol. 2019;57(2):87\u2013105.","journal-title":"Folia Neuropathol"},{"issue":"5123","key":"1226_CR56","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u20133.","journal-title":"Science"},{"issue":"16","key":"1226_CR57","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349\u201356.","journal-title":"JAMA"},{"issue":"1","key":"1226_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000334607","volume":"38","author":"A Ward","year":"2012","unstructured":"Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4\/4) among patients diagnosed with Alzheimer\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38(1):1\u201317.","journal-title":"Neuroepidemiology"},{"key":"1226_CR59","doi-asserted-by":"crossref","unstructured":"Smolic T, Zorec R, Vardjan N. Pathophysiology of lipid droplets in neuroglia. Antioxidants (Basel). 2021;11(1).","DOI":"10.3390\/antiox11010022"},{"key":"1226_CR60","first-page":"1030","volume":"145","author":"T Wisniewski","year":"1994","unstructured":"Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer\u2019s fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030\u20135.","journal-title":"Am J Pathol"},{"key":"1226_CR61","doi-asserted-by":"crossref","unstructured":"Xu H, Fu J, Mohammed Nazar RB, Yang J, Chen S, Huang Y, et al. Investigation of the relationship between apolipoprotein E alleles and serum lipids in Alzheimer\u2019s disease: a meta-analysis. Brain Sci. 2023;13(11).","DOI":"10.3390\/brainsci13111554"},{"issue":"1","key":"1226_CR62","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12916-019-1299-4","volume":"17","author":"M Safieh","year":"2019","unstructured":"Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease. BMC Med. 2019;17(1):64.","journal-title":"BMC Med"},{"issue":"10 Pt A","key":"1226_CR63","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.bbalip.2017.07.004","volume":"1862","author":"TG Nock","year":"2017","unstructured":"Nock TG, Chouinard-Watkins R, Plourde M. Carriers of an apolipoprotein E epsilon 4 allele are more vulnerable to a dietary deficiency in omega-3 fatty acids and cognitive decline. Biochimica et Biophysica Acta (BBA). 2017;1862(10 Pt A):1068\u201378.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"11","key":"1226_CR64","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nrn2009","volume":"7","author":"J Herz","year":"2006","unstructured":"Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci. 2006;7(11):850\u20139.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"1226_CR65","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.neuron.2014.08.005","volume":"83","author":"C Lane-Donovan","year":"2014","unstructured":"Lane-Donovan C, Philips GT, Herz J. More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron. 2014;83(4):771\u201387.","journal-title":"Neuron"},{"issue":"8","key":"1226_CR66","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1523\/JNEUROSCI.5471-06.2007","volume":"27","author":"H Hayashi","year":"2007","unstructured":"Hayashi H, Campenot RB, Vance DE, Vance JE. Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J Neurosci Off J Soc Neurosci. 2007;27(8):1933\u201341.","journal-title":"J Neurosci Off J Soc Neurosci."},{"issue":"14","key":"1226_CR67","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1523\/JNEUROSCI.5180-14.2015","volume":"35","author":"CC Liu","year":"2015","unstructured":"Liu CC, Hu J, Tsai CW, Yue M, Melrose HL, Kanekiyo T, et al. Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. J Neurosci Off J Soc Neurosci. 2015;35(14):5851\u20139.","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"4","key":"1226_CR68","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.4049\/jimmunol.1002847","volume":"186","author":"DJ Christensen","year":"2011","unstructured":"Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F, et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol. 2011;186(4):2535\u201342.","journal-title":"J Immunol"},{"issue":"10","key":"1226_CR69","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","volume":"73","author":"C Holmes","year":"2009","unstructured":"Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73(10):768\u201374.","journal-title":"Neurology"},{"issue":"1","key":"1226_CR70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/nyas.14907","volume":"1518","author":"I Asante","year":"2022","unstructured":"Asante I, Louie S, Yassine HN. Uncovering mechanisms of brain inflammation in Alzheimer\u2019s disease with APOE4: application of single cell-type lipidomics. Ann NY Acad Sci. 2022;1518(1):84\u2013105.","journal-title":"Ann NY Acad Sci"},{"issue":"7","key":"1226_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111200","volume":"40","author":"L Arnaud","year":"2022","unstructured":"Arnaud L, Benech P, Greetham L, Stephan D, Jimenez A, Jullien N, et al. APOE4 drives inflammation in human astrocytes via TAGLN3 repression and NF-kappaB activation. Cell Rep. 2022;40(7):111200.","journal-title":"Cell Rep"},{"issue":"2","key":"1226_CR72","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3233\/JAD-200982","volume":"78","author":"P Duarte-Guterman","year":"2020","unstructured":"Duarte-Guterman P, Albert AY, Inkster AM, Barha CK, Galea LAM, Alzheimer\u2019s Disease Neuroimaging I. Inflammation in Alzheimer\u2019s disease: do sex and APOE matter? J Alzheimers Dis. 2020;78(2):627\u201341.","journal-title":"J Alzheimers Dis"},{"key":"1226_CR73","doi-asserted-by":"crossref","unstructured":"Schonknecht YB, Crommen S, Stoffel-Wagner B, Coenen M, Fimmers R, Stehle P, et al. APOE varepsilon4 is associated with postprandial inflammation in older adults with metabolic syndrome traits. Nutrients. 2021;13(11).","DOI":"10.3390\/nu13113924"},{"issue":"1","key":"1226_CR74","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/alz.12683","volume":"19","author":"T Ashleigh","year":"2023","unstructured":"Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer\u2019s disease pathogenesis. Alzheimers Dement. 2023;19(1):333\u201342.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1226_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e14387","volume":"9","author":"AS Olagunju","year":"2023","unstructured":"Olagunju AS, Ahammad F, Alagbe AA, Otenaike TA, Teibo JO, Mohammad F, et al. Mitochondrial dysfunction: a notable contributor to the progression of Alzheimer\u2019s and Parkinson\u2019s disease. Heliyon. 2023;9(3):e14387.","journal-title":"Heliyon"},{"issue":"1","key":"1226_CR76","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.mehy.2003.12.045","volume":"63","author":"RH Swerdlow","year":"2004","unstructured":"Swerdlow RH, Khan SM. A \u201cmitochondrial cascade hypothesis\u201d for sporadic Alzheimer\u2019s disease. Med Hypotheses. 2004;63(1):8\u201320.","journal-title":"Med Hypotheses"},{"issue":"1","key":"1226_CR77","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","volume":"18","author":"MT Henrich","year":"2023","unstructured":"Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson\u2019s disease\u2014a key disease hallmark with therapeutic potential. Mol Neurodegener. 2023;18(1):83.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"1226_CR78","doi-asserted-by":"publisher","first-page":"754","DOI":"10.4103\/1673-5374.322430","volume":"17","author":"F Rey","year":"2022","unstructured":"Rey F, Ottolenghi S, Zuccotti GV, Samaja M, Carelli S. Mitochondrial dysfunctions in neurodegenerative diseases: role in disease pathogenesis, strategies for analysis and therapeutic prospects. Neural Regen Res. 2022;17(4):754\u20138.","journal-title":"Neural Regen Res"},{"key":"1226_CR79","doi-asserted-by":"crossref","unstructured":"Clemente-Suarez VJ, Redondo-Florez L, Beltran-Velasco AI, Ramos-Campo DJ, Belinchon-deMiguel P, Martinez-Guardado I, et al. Mitochondria and brain disease: a comprehensive review of pathological mechanisms and therapeutic opportunities. Biomedicines. 2023;11(9).","DOI":"10.3390\/biomedicines11092488"},{"key":"1226_CR80","doi-asserted-by":"crossref","unstructured":"Kitada T, Ardah MT, Haque ME. History of Parkinson\u2019s disease-associated gene, parkin: research over a quarter century in quest of finding the physiological substrate. Int J Mol Sci. 2023;24(23).","DOI":"10.3390\/ijms242316734"},{"key":"1226_CR81","doi-asserted-by":"crossref","unstructured":"Broadway BJ, Boneski PK, Bredenberg JM, Kolicheski A, Hou X, Soto-Beasley AI, et al. Systematic functional analysis of PINK1 and PRKN coding variants. Cells. 2022;11(15).","DOI":"10.3390\/cells11152426"},{"issue":"2","key":"1226_CR82","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","volume":"85","author":"AM Pickrell","year":"2015","unstructured":"Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease. Neuron. 2015;85(2):257\u201373.","journal-title":"Neuron"},{"key":"1226_CR83","volume":"8","author":"MKSC Angelim","year":"2025","unstructured":"Angelim MKSC. Mitochondrial therapies for neurodegenerative diseases: emerging approaches and challenges. Prem J Sci. 2025;8:100068.","journal-title":"Prem J Sci."},{"key":"1226_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2023.102694","volume":"79","author":"C Carvalho","year":"2023","unstructured":"Carvalho C, Moreira PI. Metabolic defects shared by Alzheimer\u2019s disease and diabetes: a focus on mitochondria. Curr Opin Neurobiol. 2023;79:102694.","journal-title":"Curr Opin Neurobiol"},{"key":"1226_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11112167","author":"MC Jurc\u0103u","year":"2022","unstructured":"Jurc\u0103u MC, Andronie-Cioara FL, Jurc\u0103u A, Marcu F, \u0162i\u021b DM, Pa\u0219cal\u0103u N, et al. The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer\u2019s disease: therapeutic implications and future perspectives. Antioxidants (Basel). 2022. https:\/\/doi.org\/10.3390\/antiox11112167.","journal-title":"Antioxidants (Basel)"},{"issue":"95","key":"1226_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102118","volume":"28","author":"TD Muller","year":"2025","unstructured":"Muller TD, Adriaenssens A, Ahren B, Bluher M, Birkenfeld AL, Campbell JE, et al. Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab. 2025;28(95):102118.","journal-title":"Mol Metab."},{"issue":"2","key":"1226_CR87","first-page":"117","volume":"7","author":"H Harada","year":"2003","unstructured":"Harada H, Grant S. Apoptosis regulators. Rev Clin Exp Hematol. 2003;7(2):117\u201338.","journal-title":"Rev Clin Exp Hematol"},{"key":"1226_CR88","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fnagi.2019.00088","volume":"11","author":"C H\u00f6lscher","year":"2019","unstructured":"H\u00f6lscher C. Insulin signaling impairment in the brain as a risk factor in Alzheimer\u2019s disease. Front Aging Neurosci. 2019;11:88.","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"1226_CR89","doi-asserted-by":"publisher","first-page":"26797","DOI":"10.3390\/ijms161125990","volume":"16","author":"Y Kiriyama","year":"2015","unstructured":"Kiriyama Y, Nochi H. The function of autophagy in neurodegenerative diseases. Int J Mol Sci. 2015;16(11):26797\u2013812.","journal-title":"Int J Mol Sci"},{"key":"1226_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.970925","volume":"16","author":"N Reich","year":"2022","unstructured":"Reich N, H\u00f6lscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review. Front Neurosci. 2022;16:970925.","journal-title":"Front Neurosci"},{"issue":"2\u20133","key":"1226_CR91","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.exger.2010.08.026","volume":"46","author":"C Benedict","year":"2011","unstructured":"Benedict C, Frey WH 2nd, Schioth HB, Schultes B, Born J, Hallschmid M. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol. 2011;46(2\u20133):112\u20135.","journal-title":"Exp Gerontol"},{"issue":"3","key":"1226_CR92","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JAD-150307","volume":"47","author":"TS Salameh","year":"2015","unstructured":"Salameh TS, Bullock KM, Hujoel IA, Niehoff ML, Wolden-Hanson T, Kim J, et al. Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J Alzheimers Dis. 2015;47(3):715\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"1226_CR93","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","volume":"27","author":"J Freiherr","year":"2013","unstructured":"Freiherr J, Hallschmid M, Frey WH, Brunner YF 2nd, Chapman CD, Holscher C, et al. Intranasal insulin as a treatment for Alzheimer\u2019s disease: a review of basic research and clinical evidence. CNS Drugs. 2013;27(7):505\u201314.","journal-title":"CNS Drugs"},{"issue":"1","key":"1226_CR94","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29\u201338.","journal-title":"Arch Neurol"},{"issue":"9","key":"1226_CR95","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","volume":"77","author":"S Craft","year":"2020","unstructured":"Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77(9):1099\u2013109.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1226_CR96","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41598-022-05165-3","volume":"12","author":"D Kellar","year":"2022","unstructured":"Kellar D, Register T, Lockhart SN, Aisen P, Raman R, Rissman RA, et al. Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer\u2019s disease: a randomized trial. Sci Rep. 2022;12(1):1346.","journal-title":"Sci Rep"},{"issue":"3","key":"1226_CR97","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3233\/JAD-141791","volume":"44","author":"A Claxton","year":"2015","unstructured":"Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer\u2019s disease dementia. J Alzheimers Dis. 2015;44(3):897\u2013906.","journal-title":"J Alzheimers Dis"},{"issue":"1S","key":"1226_CR98","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jalz.2013.12.006","volume":"10","author":"C H\u00f6lscher","year":"2014","unstructured":"H\u00f6lscher C. First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(1S):S33\u20137.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1226_CR99","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131\u201357.","journal-title":"Gastroenterology"},{"issue":"6","key":"1226_CR100","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3233\/JAD-2002-4605","volume":"4","author":"T Perry","year":"2002","unstructured":"Perry T, Greig NH. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer\u2019s disease. J Alzheimers Dis. 2002;4(6):487\u201396.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1226_CR101","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.pneurobio.2006.06.003","volume":"79","author":"LP van der Heide","year":"2006","unstructured":"van der Heide LP, Ramakers GM, Smidt MP. Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol. 2006;79(4):205\u201321.","journal-title":"Prog Neurobiol"},{"issue":"3","key":"1226_CR102","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","volume":"113","author":"ME Doyle","year":"2007","unstructured":"Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113(3):546\u201393.","journal-title":"Pharmacol Ther"},{"key":"1226_CR103","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72\u2013130.","journal-title":"Mol Metab."},{"issue":"3","key":"1226_CR104","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1124\/mol.111.074757","volume":"81","author":"D Schelshorn","year":"2012","unstructured":"Schelshorn D, Joly F, Mutel S, Hampe C, Breton B, Mutel V, et al. Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Mol Pharmacol. 2012;81(3):309\u201318.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"1226_CR105","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2337\/db12-0988","volume":"62","author":"V Darsalia","year":"2013","unstructured":"Darsalia V, Orts\u00e4ter H, Olverling A, Darl\u00f6f E, Wolbert P, Nystr\u00f6m T, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2013;62(4):1289\u201396.","journal-title":"Diabetes"},{"issue":"9","key":"1226_CR106","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm919","volume":"9","author":"MJ During","year":"2003","unstructured":"During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173\u20139.","journal-title":"Nat Med"},{"key":"1226_CR107","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/WNR.0b013e32832fbf14","volume":"20","author":"A Hamilton","year":"2009","unstructured":"Hamilton A, Holscher C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. NeuroReport. 2009;20:1161\u20136.","journal-title":"NeuroReport"},{"issue":"106","key":"1226_CR108","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0806720106","volume":"21","author":"Y Li","year":"2009","unstructured":"Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA. 2009;21(106):1285\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"1226_CR109","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","volume":"4","author":"SC Cork","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015;4(10):718\u201331.","journal-title":"Mol Metab"},{"issue":"14","key":"1226_CR110","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/cne.24905","volume":"528","author":"DL Graham","year":"2020","unstructured":"Graham DL, Durai HH, Trammell TS, Noble BL, Mortlock DP, Galli A, et al. A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain. J Comp Neurol. 2020;528(14):2445\u201370.","journal-title":"J Comp Neurol"},{"issue":"2","key":"1226_CR111","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0196-9781(94)90016-7","volume":"15","author":"AM Kaplan","year":"1994","unstructured":"Kaplan AM, Vigna SR. Gastric inhibitory polypeptide (GIP) binding sites in rat brain. Peptides. 1994;15(2):297\u2013302.","journal-title":"Peptides"},{"issue":"6","key":"1226_CR112","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","volume":"133","author":"TB Usdin","year":"1993","unstructured":"Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 1993;133(6):2861\u201370.","journal-title":"Endocrinology"},{"issue":"7","key":"1226_CR113","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1523\/JNEUROSCI.4920-04.2005","volume":"25","author":"J Nyberg","year":"2005","unstructured":"Nyberg J, Anderson MF, Meister B, Alborn AM, Strom AK, Brederlau A, et al. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci. 2005;25(7):1816\u201325.","journal-title":"J Neurosci"},{"issue":"85","key":"1226_CR114","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/jnr.21349","volume":"17","author":"J Nyberg","year":"2007","unstructured":"Nyberg J, Jacobsson C, Anderson MF, Eriksson PS. Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J Neurosci Res. 2007;17(85):2099\u2013119.","journal-title":"J Neurosci Res"},{"issue":"3","key":"1226_CR115","doi-asserted-by":"publisher","first-page":"11","DOI":"10.11648\/j.ajbio.20150301.13","volume":"1","author":"R Ohshima","year":"2015","unstructured":"Ohshima R, Hotsumi K, Holscher C, Seki K. Age-related decrease in glucagon-like peptide-1 in mouse prefrontal cortex but not in hippocampus despite the preservation of its receptor. Am J Biosci. 2015;1(3):11\u201327.","journal-title":"Am J Biosci"},{"issue":"4","key":"1226_CR116","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.neures.2006.04.008","volume":"55","author":"T Iwai","year":"2006","unstructured":"Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res. 2006;55(4):352\u201360.","journal-title":"Neurosci Res"},{"key":"1226_CR117","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/1742-2094-9-276","volume":"9","author":"C Kappe","year":"2012","unstructured":"Kappe C, Tracy LM, Patrone C, Iverfeldt K, Sjoholm A. GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J Neuroinflamm. 2012;9:276.","journal-title":"J Neuroinflamm"},{"key":"1226_CR118","doi-asserted-by":"crossref","unstructured":"Diz-Chaves Y, Mastoor Z, Spuch C, Gonzalez-Matias LC, Mallo F. Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases. Int J Mol Sci. 2022;23(17).","DOI":"10.3390\/ijms23179583"},{"key":"1226_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170184","volume":"125","author":"ZQ Zhang","year":"2020","unstructured":"Zhang ZQ, Holscher C. GIP has neuroprotective effects in Alzheimer and Parkinson\u2019s disease models. Peptides. 2020;125:170184.","journal-title":"Peptides"},{"key":"1226_CR120","doi-asserted-by":"crossref","unstructured":"Duarte AI, Candeias E, Alves IN, Mena D, Silva DF, Machado NJ, et al. Liraglutide protects against brain amyloid-beta1-42 accumulation in female mice with early Alzheimer\u2019s disease-like pathology by partially rescuing oxidative\/nitrosative stress and inflammation. Int J Mol Sci. 2020 Mar 4;21(5).","DOI":"10.3390\/ijms21051746"},{"key":"1226_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"M Gejl","year":"2016","unstructured":"Gejl M, Gjedde A, Egefjord L, M\u00f8ller A, Hansen SB, Vang K, et al. In Alzheimer\u2019s disease, six-month treatment with GLP-1 analogue prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:1\u201310.","journal-title":"Front Aging Neurosci"},{"issue":"240","key":"1226_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109716","volume":"18","author":"ZJ Wang","year":"2023","unstructured":"Wang ZJ, Li XR, Chai SF, Li WR, Li S, Hou M, et al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway. Neuropharmacology. 2023;18(240):109716.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1226_CR123","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","volume":"22","author":"RA Fontanella","year":"2024","unstructured":"Fontanella RA, Ghosh P, Pesapane A, Taktaz F, Puocci A, Franzese M, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med. 2024;22(1):114.","journal-title":"J Transl Med"},{"issue":"1 Suppl","key":"1226_CR124","first-page":"S12","volume":"10","author":"K Talbot","year":"2014","unstructured":"Talbot K, Wang HY. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(1 Suppl):S12-25.","journal-title":"Alzheimers Dement"},{"issue":"Suppl 1","key":"1226_CR125","first-page":"S263","volume":"33","author":"S Craft","year":"2013","unstructured":"Craft S, Cholerton B, Baker LD. Insulin and Alzheimer\u2019s disease: untangling the web. J Alzheimers Dis. 2013;33(Suppl 1):S263\u201375.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1226_CR126","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-2005-7107","volume":"7","author":"E Steen","year":"2005","unstructured":"Steen E, Terry BM, Rivera E, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease - Is this type 3 diabetes? J Alzheimer\u2019s Dis. 2005;7(1):63\u201380.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"1226_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-51","volume":"11","author":"IA Clark","year":"2014","unstructured":"Clark IA, Vissel B. Inflammation-sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflamm. 2014;11:51.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"1226_CR128","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","volume":"15","author":"CM Long-Smith","year":"2013","unstructured":"Long-Smith CM, Manning S, McClean PL, Coakley MF, O\u2019Halloran DJ, Holscher C, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer\u2019s disease. NeuroMol Med. 2013;15(1):102\u201314.","journal-title":"NeuroMol Med"},{"issue":"2\u20133","key":"1226_CR129","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ejphar.2011.11.005","volume":"674","author":"L Li","year":"2012","unstructured":"Li L, Zhang ZF, Holscher C, Gao C, Jiang YH, Liu YZ. (Val(8)) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol. 2012;674(2\u20133):280\u20136.","journal-title":"Eur J Pharmacol"},{"key":"1226_CR130","doi-asserted-by":"publisher","first-page":"1428817","DOI":"10.1155\/2022\/1428817","volume":"2022","author":"L Zhang","year":"2022","unstructured":"Zhang L, Li C, Zhang Z, Zhang Z, Jin QQ, Li L, et al. DA5-CH and semaglutide protect against neurodegeneration and reduce alpha-synuclein levels in the 6-OHDA Parkinson\u2019s disease rat model. Parkinson\u2019s Dis. 2022;2022:1428817.","journal-title":"Parkinson\u2019s Dis"},{"issue":"8","key":"1226_CR131","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.4103\/1673-5374.389361","volume":"16","author":"LY Zhang","year":"2021","unstructured":"Zhang LY, Jin QQ, Holscher C, Li L. Glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural Regen Res. 2021;16(8):1660\u201370.","journal-title":"Neural Regen Res"},{"issue":"6","key":"1226_CR132","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cmet.2013.11.002","volume":"18","author":"MV Lourenco","year":"2013","unstructured":"Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, et al. TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer\u2019s beta-amyloid oligomers in mice and monkeys. Cell Metab. 2013;18(6):831\u201343.","journal-title":"Cell Metab"},{"issue":"1","key":"1226_CR133","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.5056","volume":"245","author":"AF Batista","year":"2018","unstructured":"Batista AF, Forny-Germano L, Clarke JR, Lyra ESNM, Brito-Moreira J, Boehnke SE, et al. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease. J Pathol. 2018;245(1):85\u2013100.","journal-title":"J Pathol"},{"key":"1226_CR134","doi-asserted-by":"publisher","first-page":"e01505","DOI":"10.1002\/brb3.1505","volume":"10","author":"C Li","year":"2020","unstructured":"Li C, Liu W, Li X, Zhang Z, Qi H, Liu S, et al. The novel GLP-1\/GIP Analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD. Brain and Behavior. 2020;10:e01505.","journal-title":"Brain and Behavior"},{"issue":"327","key":"1226_CR135","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bbr.2017.03.032","volume":"01","author":"L Shi","year":"2017","unstructured":"Shi L, Zhang Z, Li L, Holscher C. A novel dual GLP-1\/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res. 2017;01(327):65\u201374.","journal-title":"Behav Brain Res"},{"key":"1226_CR136","doi-asserted-by":"crossref","unstructured":"Feng P, Zhang X, Li D, J C, Yuan Z, Wang R, et al. Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology. 2018;133:385\u201394.","DOI":"10.1016\/j.neuropharm.2018.02.012"},{"issue":"318","key":"1226_CR137","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbr.2016.10.033","volume":"01","author":"HY Cai","year":"2017","unstructured":"Cai HY, Wang ZJ, Holscher C, Yuan L, Zhang J, Sun P, et al. Lixisenatide attenuates the detrimental effects of amyloid beta protein on spatial working memory and hippocampal neurons in rats. Behav Brain Res. 2017;01(318):28\u201335.","journal-title":"Behav Brain Res"},{"key":"1226_CR138","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.02.013","volume":"117","author":"J Jalewa","year":"2017","unstructured":"Jalewa J, Sharma M, Gengler S, H\u00f6lscher C. A novel GLP-1\/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson\u2019s disease. Neuropharmacology. 2017;117:238\u201348.","journal-title":"Neuropharmacology"},{"issue":"3","key":"1226_CR139","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/jnc.12469","volume":"128","author":"MK Sharma","year":"2014","unstructured":"Sharma MK, Jalewa J, Holscher C. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J Neurochem. 2014;128(3):459\u201371.","journal-title":"J Neurochem"},{"issue":"1","key":"1226_CR140","doi-asserted-by":"publisher","first-page":"16158","DOI":"10.1038\/s41598-017-16488-x","volume":"7","author":"T Panagaki","year":"2017","unstructured":"Panagaki T, Michael M, H\u00f6lscher C. Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells. Sci Rep. 2017;7(1):16158.","journal-title":"Sci Rep"},{"issue":"1","key":"1226_CR141","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jnc.13736","volume":"139","author":"J Jalewa","year":"2016","unstructured":"Jalewa J, Sharma MK, Holscher C. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. J Neurochem. 2016;139(1):55\u201367.","journal-title":"J Neurochem"},{"key":"1226_CR142","doi-asserted-by":"crossref","unstructured":"Yu YW, Hsueh SC, Lai JH, Chen YH, Kang SJ, Chen KY, et al. Glucose-dependent insulinotropic polypeptide mitigates 6-OHDA-induced behavioral impairments in Parkinsonian rats. Int J Mol Sci. 2018;19(4).","DOI":"10.3390\/ijms19041153"},{"issue":"66","key":"1226_CR143","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JAD-180584","volume":"25","author":"T Panagaki","year":"2018","unstructured":"Panagaki T, Gengler S, Holscher C. The novel DA-CH3 dual incretin restores endoplasmic reticulum stress and autophagy impairments to attenuate Alzheimer-like pathology and cognitive decrements in the APPSWE\/PS1DeltaE9 mouse model. J Alzheimer\u2019s Dis. 2018;25(66):195\u2013218.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1226_CR144","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","volume":"827","author":"Y Cao","year":"2018","unstructured":"Cao Y, Holscher C, Hu MM, Wang T, Zhao F, Bai Y, et al. DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer\u2019s disease. Eur J Pharmacol. 2018;827:215\u201326.","journal-title":"Eur J Pharmacol"},{"issue":"277C","key":"1226_CR145","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.neuroscience.2014.02.022","volume":"27","author":"HY Cai","year":"2014","unstructured":"Cai HY, Holscher C, Yue XH, Zhang SX, Wang XH, Qiao F, et al. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats. Neuroscience. 2014;27(277C):6\u201313.","journal-title":"Neuroscience"},{"issue":"1","key":"1226_CR146","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2019.01.103","volume":"511","author":"M Zhou","year":"2019","unstructured":"Zhou M, Chen S, Peng P, Gu Z, Yu J, Zhao G, et al. Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3beta. Biochem Biophys Res Commun. 2019;511(1):154\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"1226_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.yhbeh.2019.104640","volume":"118","author":"ZJ Wang","year":"2020","unstructured":"Wang ZJ, Han YF, Zhao F, Yang GZ, Yuan L, Cai HY, et al. A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP\/PS1 transgenic mice. Horm Behav. 2020;118:104640.","journal-title":"Horm Behav"},{"key":"1226_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101180","volume":"47","author":"J Zheng","year":"2021","unstructured":"Zheng J, Xie Y, Ren L, Qi L, Wu L, Pan X, et al. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer\u2019s disease. Mol Metab. 2021;47:101180.","journal-title":"Mol Metab"},{"issue":"7","key":"1226_CR149","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3233\/JPD-230030","volume":"13","author":"T Panagaki","year":"2023","unstructured":"Panagaki T, Randi EB, Szabo C, Holscher C. Incretin mimetics restore the ER-mitochondrial axis and switch cell fate towards survival in LUHMES dopaminergic-like neurons: implications for novel therapeutic strategies in Parkinson\u2019s disease. J Parkinsons Dis. 2023;13(7):1149\u201374.","journal-title":"J Parkinsons Dis"},{"key":"1226_CR150","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","volume":"303","author":"W Liu","year":"2015","unstructured":"Liu W, Jalewa J, Sharma M, Li G, Li L, H\u00f6lscher C. Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson\u2019s disease. Neuroscience. 2015;303:42\u201350.","journal-title":"Neuroscience"},{"issue":"6","key":"1226_CR151","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1111\/j.1471-4159.2010.06731.x","volume":"113","author":"Y Li","year":"2010","unstructured":"Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem. 2010;113(6):1621\u201331.","journal-title":"J Neurochem"},{"issue":"2","key":"1226_CR152","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/1673-5374.177742","volume":"11","author":"L Li","year":"2016","unstructured":"Li L, Liu K, Zhao J, Holscher C, Li GL, Liu YZ. Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson\u2019s disease. Neural Regen Res. 2016;11(2):326\u201331.","journal-title":"Neural Regen Res"},{"key":"1226_CR153","first-page":"1","volume":"20250013","author":"X Yang","year":"2025","unstructured":"Yang X, Feng P, Zhu H, Wang M, Li N, Bai B, et al. Semaglutide to remodel mitochondrial dynamics and mitophagy balance for vascular dementia therapy. View. 2025;20250013:1\u201322.","journal-title":"View"},{"key":"1226_CR154","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neuropharm.2015.10.002","volume":"101","author":"Y Li","year":"2016","unstructured":"Li Y, Liu W, Li L, Holscher C. Neuroprotective effects of a GIP analogue in the MPTP Parkinson\u2019s disease mouse model. Neuropharmacology. 2016;101:255\u201363.","journal-title":"Neuropharmacology"},{"issue":"797","key":"1226_CR155","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejphar.2016.11.050","volume":"29","author":"Y Li","year":"2017","unstructured":"Li Y, Liu W, Li L, Holscher C. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson\u2019s disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation. Eur J Pharmacol. 2017;29(797):162\u201372.","journal-title":"Eur J Pharmacol"},{"key":"1226_CR156","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","volume":"71","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhang L, Li L, Holscher C. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model. Neuropeptides. 2018;71:70\u201380.","journal-title":"Neuropeptides"},{"issue":"1","key":"1226_CR157","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhang L, Li L, Holscher C. Semaglutide is neuroprotective and reduces alpha-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease. J Parkinsons Dis. 2019;9(1):157\u201371.","journal-title":"J Parkinsons Dis"},{"issue":"1634","key":"1226_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2015.09.035","volume":"01","author":"C Ji","year":"2016","unstructured":"Ji C, Xue GF, Lijun C, Feng P, Li D, Li L, et al. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson\u2019s disease by increasing expression of BNDF. Brain Res. 2016;01(1634):1\u201311.","journal-title":"Brain Res"},{"issue":"1","key":"1226_CR159","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/a-1266-3263","volume":"71","author":"Y Su","year":"2021","unstructured":"Su Y, Zhang Z, Li H, Ma J, Sun L, Shao S, et al. A GLP-2 analogue protects SH-SY5Y and neuro-2a cells against mitochondrial damage, autophagy impairments and apoptosis in a Parkinson model. Drug Res (Stuttg). 2021;71(1):43\u201350.","journal-title":"Drug Res (Stuttg)."},{"issue":"9","key":"1226_CR160","first-page":"1556","volume":"1842","author":"I Pedros","year":"2014","unstructured":"Pedros I, Petrov D, Allgaier M, Sureda F, Barroso E, Beas-Zarate C, et al. Early alterations in energy metabolism in the hippocampus of APPswe\/PS1dE9 mouse model of Alzheimer\u2019s disease. Biochem Biophys Acta. 2014;1842(9):1556\u201366.","journal-title":"Biochem Biophys Acta"},{"key":"1226_CR161","doi-asserted-by":"crossref","unstructured":"Atlante A, Amadoro G, Latina V, Valenti D. Therapeutic potential of targeting mitochondria for Alzheimer\u2019s disease treatment. J Clin Med. 2022;11(22).","DOI":"10.3390\/jcm11226742"},{"issue":"2","key":"1226_CR162","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4103\/1673-5374.317957","volume":"17","author":"JD Panes","year":"2022","unstructured":"Panes JD, Wendt A, Ramirez-Molina O, Castro PA, Fuentealba J. Deciphering the role of PGC-1alpha in neurological disorders: from mitochondrial dysfunction to synaptic failure. Neural Regen Res. 2022;17(2):237\u201345.","journal-title":"Neural Regen Res"},{"issue":"370","key":"1226_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.111932","volume":"16","author":"J An","year":"2019","unstructured":"An J, Zhou Y, Zhang M, Xie Y, Ke S, Liu L, et al. Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5xFAD mouse model of Alzheimer\u2019s disease. Behav Brain Res. 2019;16(370):111932.","journal-title":"Behav Brain Res"},{"issue":"2","key":"1226_CR164","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3233\/JAD-210256","volume":"83","author":"HY Cai","year":"2021","unstructured":"Cai HY, Yang D, Qiao J, Yang JT, Wang ZJ, Wu MN, et al. A GLP-1\/GIP dual receptor agonist DA4-JC effectively attenuates cognitive impairment and pathology in the APP\/PS1\/Tau model of Alzheimer\u2019s disease. J Alzheimers Dis. 2021;83(2):799\u2013818.","journal-title":"J Alzheimers Dis"},{"key":"1226_CR165","first-page":"7427136","volume":"2023","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Shi M, Li Z, Ling Y, Zhai L, Yuan Y, et al. A dual GLP-1\/GIP receptor agonist is more effective than liraglutide in the A53T mouse model of Parkinson\u2019s disease. Parkinson\u2019s Dis. 2023;2023:7427136.","journal-title":"Parkinson\u2019s Dis"},{"key":"1226_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550","volume":"186","author":"KO Kopp","year":"2022","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res. 2022;186:106550.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1226_CR167","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1210\/jc.2011-1508","volume":"97","author":"A Chaudhuri","year":"2012","unstructured":"Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab. 2012;97(1):198\u2013207.","journal-title":"J Clin Endocrinol Metab"},{"key":"1226_CR168","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"P McClean","year":"2011","unstructured":"McClean P, Parthsarathy V, Faivre E, H\u00f6lscher C. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2011;31:6587\u201394.","journal-title":"J Neurosci"},{"issue":"Pt A","key":"1226_CR169","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","volume":"76","author":"PL McClean","year":"2014","unstructured":"McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease. Neuropharmacology. 2014;76(Pt A):57\u201367.","journal-title":"Neuropharmacology"},{"issue":"86C","key":"1226_CR170","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","volume":"8","author":"PL McClean","year":"2014","unstructured":"McClean PL, Holscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease. Neuropharmacology. 2014;8(86C):241\u201358.","journal-title":"Neuropharmacology"},{"issue":"563","key":"1226_CR171","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.neuroscience.2024.11.022","volume":"13","author":"ZJ Wang","year":"2024","unstructured":"Wang ZJ, Han WN, Chai SF, Li Y, Fu CJ, Wang CF, et al. Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP\/PS1\/tau mice. Neuroscience. 2024;13(563):222\u201334.","journal-title":"Neuroscience"},{"key":"1226_CR172","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbr.2015.07.021","volume":"293","author":"YF Zhang","year":"2015","unstructured":"Zhang YF, Chen YM, Li L, H\u00f6lscher C. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson\u2019s disease mouse model. Behav Brain Res. 2015;293:107\u201313.","journal-title":"Behav Brain Res"},{"issue":"228","key":"1226_CR173","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.neuroscience.2012.10.045","volume":"3","author":"AM Duffy","year":"2013","unstructured":"Duffy AM, Holscher C. The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP\/PS1 mouse model of Alzheimer\u2019s disease. Neuroscience. 2013;3(228):294\u2013300.","journal-title":"Neuroscience"},{"issue":"2","key":"1226_CR174","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/alzrt174","volume":"5","author":"E Faivre","year":"2013","unstructured":"Faivre E, Holscher C. Neuroprotective effects of D-Ala2GIP on Alzheimer\u2019s disease biomarkers in an APP\/PS1 mouse model. Alzheimer\u2019s Res Therapy. 2013;5(2):20\u20138.","journal-title":"Alzheimer\u2019s Res Therapy."},{"key":"1226_CR175","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/WNR.0000000000000548","volume":"37","author":"L Cao","year":"2016","unstructured":"Cao L, Li D, Feng P, Li L, Xue G, Li G, et al. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson\u2019s disease by reducing chronic inflammation in the brain. NeuroReport. 2016;37:384\u201391.","journal-title":"NeuroReport"},{"issue":"812","key":"1226_CR176","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","volume":"05","author":"Z Yuan","year":"2017","unstructured":"Yuan Z, Li D, Feng P, Xue G, Ji C, Li G, et al. A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson\u2019s disease. Eur J Pharmacol. 2017;05(812):82\u201390.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"1226_CR177","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2231","volume":"11","author":"M Lv","year":"2021","unstructured":"Lv M, Xue G, Cheng H, Meng P, Lian X, Holscher C, et al. The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-kappaB inflammatory pathway in the MPTP mouse model of Parkinson\u2019s disease more effectively than the GLP-1 single-receptor agonist NLY01. Brain Behav. 2021;11(8):e2231.","journal-title":"Brain Behav"},{"issue":"1\u20133","key":"1226_CR178","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejphar.2012.12.012","volume":"700","author":"V Parthsarathy","year":"2013","unstructured":"Parthsarathy V, Holscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol. 2013;700(1\u20133):42\u201350.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1226_CR179","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1533317511412046","volume":"26","author":"E Matteau","year":"2011","unstructured":"Matteau E, Dupre N, Langlois M, Jean L, Thivierge S, Provencher P, et al. Mattis dementia rating scale 2: screening for MCI and dementia. Am J Alzheimers Dis Other Dement. 2011;26(5):389\u201398.","journal-title":"Am J Alzheimers Dis Other Dement"},{"issue":"11","key":"1226_CR180","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/mds.22173","volume":"23","author":"G Llebaria","year":"2008","unstructured":"Llebaria G, Pagonabarraga J, Kulisevsky J, Garcia-Sanchez C, Pascual-Sedano B, Gironell A, et al. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson\u2019s disease. Mov Disord. 2008;23(11):1546\u201350.","journal-title":"Mov Disord"},{"issue":"6","key":"1226_CR181","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0166-2236(02)02181-1","volume":"25","author":"R de la Fuente-Fernandez","year":"2002","unstructured":"de la Fuente-Fernandez R, Stoessl AJ. The placebo effect in Parkinson\u2019s disease. Trends Neurosci. 2002;25(6):302\u20136.","journal-title":"Trends Neurosci"},{"issue":"13","key":"1226_CR182","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","volume":"03","author":"D Aarsland","year":"2017","unstructured":"Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;03(13):217\u201331.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"1226_CR183","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Investig. 2013;123(6):2730\u20136.","journal-title":"J Clin Investig"},{"issue":"17","key":"1226_CR184","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(17):1664\u201375.","journal-title":"Lancet"},{"issue":"2","key":"1226_CR185","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JPD-181329","volume":"8","author":"D Athauda","year":"2018","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, et al. What effects might exenatide have on non-motor symptoms in Parkinson\u2019s disease: a post hoc analysis. J Parkinsons Dis. 2018;8(2):247\u201358.","journal-title":"J Parkinsons Dis"},{"issue":"76","key":"1226_CR186","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","volume":"14","author":"D Athauda","year":"2019","unstructured":"Athauda D, Gulyani S, Karnati H, Li Y, Tweedie D, Mustapic M, et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol. 2019;14(76):420\u20139.","journal-title":"JAMA Neurol"},{"key":"1226_CR187","doi-asserted-by":"publisher","unstructured":"Athauda D, Evans JR, Mahoney-Sanchez L, Virdi GS, Lopez-Garcia P, Wernick A, et al. GLP1 receptor agonism ameliorates Parkinson\u2019s disease through modulation of neuronal insulin signalling and glial suppression. bioRxiv preprint. 2024.https:\/\/doi.org\/10.1101\/2024.02.28.582460.","DOI":"10.1101\/2024.02.28.582460"},{"issue":"10479","key":"1226_CR188","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025;405(10479):627\u201336.","journal-title":"Lancet"},{"key":"1226_CR189","unstructured":"Foltynie T. Exenatide as a disease modifying treatment for Parkinson\u2019s disease\u2014a randomised trial. AD\/PD conference; 2025 1\u20135 April; Vienna, Austria; 2025. Abstr. ID3028."},{"issue":"8","key":"1226_CR190","first-page":"503","volume":"12","author":"M Christensen","year":"2009","unstructured":"Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs. 2009;12(8):503\u201313.","journal-title":"IDrugs"},{"key":"1226_CR191","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"W Meissner","year":"2024","unstructured":"Meissner W, Remy P, Giordana C, Maltete D, Derkinderen P, Houeto J, et al. Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med. 2024;390:1176\u201385.","journal-title":"N Engl J Med"},{"key":"1226_CR192","doi-asserted-by":"publisher","unstructured":"Hogg E, Wu T, Bresee C, Wertheimer J, Malatt C, Tan E, et al. A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson\u2019s disease. Available at SSRN. 2023. https:\/\/ssrn.com\/abstract=4212371 or: https:\/\/doi.org\/10.2139\/ssrn.4212371.","DOI":"10.2139\/ssrn.4212371"},{"issue":"4","key":"1226_CR193","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bph.15508","volume":"179","author":"C H\u00f6lscher","year":"2022","unstructured":"H\u00f6lscher C. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. Br J Pharmacol. 2022;179(4):695\u2013714.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1226_CR194","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1186\/s13063-020-04608-4","volume":"21","author":"GD Femminella","year":"2020","unstructured":"Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, et al. Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study). Trials. 2020;21(1):660.","journal-title":"Trials"},{"key":"1226_CR195","first-page":"S9","volume":"17","author":"P Edison","year":"2022","unstructured":"Edison P, Femminella G, Ritchie C, Holmes C, Walker Z, Ridha B, et al. Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease. Alzheimer Dement. 2022;17:S9.","journal-title":"Alzheimer Dement."},{"key":"1226_CR196","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/alz.080538","volume":"19","author":"P Edison","year":"2023","unstructured":"Edison P, Walker Z, Coulthard E, H\u00f6lscher C, Passmore A, Ballard C. MRI changes following treatment of GLP-1 analogue,liraglutide in Alzheimer\u2019s disease: the ELAD trial. Alzheimer Dement. 2023;19:S21.","journal-title":"Alzheimer Dement."},{"issue":"146","key":"1226_CR197","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1093\/brain\/awad159","volume":"15","author":"KP Kepp","year":"2023","unstructured":"Kepp KP, Robakis NK, Hoilund-Carlsen PF, Sensi SL, Vissel B. The amyloid cascade hypothesis: an updated critical review. Brain. 2023;15(146):3969\u201390.","journal-title":"Brain"},{"key":"1226_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114187","volume":"180","author":"TS Salameh","year":"2020","unstructured":"Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics. Biochem Pharmacol. 2020;180:114187.","journal-title":"Biochem Pharmacol"},{"issue":"suppl. 1","key":"1226_CR199","first-page":"77","volume":"38","author":"Y Kimura","year":"2023","unstructured":"Kimura Y, Koda T, Kurakami H, Sakamoto S, Iwasaki K, Mochizuki H. Trial protocol: randomized double blind controlled study to investigate disease modifying effect, safety and optimal dose of oral semaglutide tablet for patients with Parkinson\u2019s disease (MOST-ABLE study). Mov Disord. 2023;38(suppl. 1):77.","journal-title":"Mov Disord"},{"key":"1226_CR200","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, et al. Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20:8661\u201372 (Oct 24;).","journal-title":"Alzheimers Dement"},{"issue":"11","key":"1226_CR201","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/mds.29992","volume":"39","author":"H Tang","year":"2024","unstructured":"Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F, et al. Glucagon-like peptide-1 receptor agonists and risk of Parkinson\u2019s disease in patients with type 2 diabetes: a population-based cohort study. Mov Disord. 2024;39(11):1960\u201370.","journal-title":"Mov Disord"},{"key":"1226_CR202","doi-asserted-by":"crossref","unstructured":"Wang W, Davis PB, Qi X, Gurney M, Perry G, Volkow ND, et al. Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study. J. Alzheimer\u2019s Dis. 2025:13872877251351329.","DOI":"10.1177\/13872877251351329"},{"issue":"3","key":"1226_CR203","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Bluher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201\u201323.","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"1226_CR204","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","volume":"5","author":"FS Willard","year":"2020","unstructured":"Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.","journal-title":"JCI Insight."},{"issue":"209","key":"1226_CR205","doi-asserted-by":"publisher","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","volume":"5","author":"B Finan","year":"2013","unstructured":"Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151.","journal-title":"Sci Transl Med."},{"issue":"18","key":"1226_CR206","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370\u201380.","journal-title":"J Med Chem"},{"key":"1226_CR207","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.2147\/DMSO.S375559","volume":"15","author":"M Dong","year":"2022","unstructured":"Dong M, Wen S, Zhou L. The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Diabetes Metab Syndr Obes. 2022;15:2583\u201397.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1226_CR208","doi-asserted-by":"crossref","unstructured":"Rhea EM, Babin A, Thomas P, Omer M, Weaver R, Hansen K, et al. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases. Tissue Barriers. 2023:2292461.","DOI":"10.1080\/21688370.2023.2292461"},{"issue":"1","key":"1226_CR209","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13195-024-01537-1","volume":"16","author":"N Abdulhameed","year":"2024","unstructured":"Abdulhameed N, Babin A, Hansen K, Weaver R, Banks WA, Talbot K, et al. Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP\/PS1 mouse model of Alzheimer\u2019s disease. Alzheimer\u2019s Res Therapy. 2024;16(1):173.","journal-title":"Alzheimer\u2019s Res Therapy."},{"issue":"7","key":"1226_CR210","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med. 2018;24(7):931\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"1226_CR211","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23(1):37\u201345.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1226_CR212","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14728222.2022.2079492","volume":"26","author":"X Yang","year":"2022","unstructured":"Yang X, Feng P, Ji R, Ren Y, Wei W, Holscher C. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson\u2019s disease. Expert Opin Ther Targets. 2022;26(5):445\u201360.","journal-title":"Expert Opin Ther Targets"},{"key":"1226_CR213","doi-asserted-by":"publisher","DOI":"10.1177\/1533317520953041","volume":"35","author":"M Maskery","year":"2020","unstructured":"Maskery M, Goulding EM, Gengler S, Melchiorsen JU, Rosenkilde MM, Holscher C. The dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen. 2020;35:1533317520953041.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"1226_CR214","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JPD-191768","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhang L, Li Y, Li L, Melchiorsen J, Rosenkilde M, et al. The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson\u2019s disease. J Parkinsons Dis. 2020;10:523\u201342.","journal-title":"J Parkinsons Dis"},{"key":"1226_CR215","unstructured":"H\u00f6lscher C. Dual GLP-1\/GIP receptor agonists that can cross the BBB show superior neuroprotective effects. AD\/PD conference; 2025 1\u20135 April; Vienna, Austria; 2025. Abstr. ID2879."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01226-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01226-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01226-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:04:19Z","timestamp":1762884259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01226-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":215,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01226-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.H. is a named inventor on patents that cover GLP-1, GIP, or dual GLP-1\/GIP receptor agonists as treatments for AD and PD. He is the CSO of the biotech company Kariya Pharmaceuticals Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"I am the sole author of the article and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}